What changed
$GSK — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $1.9B | EPS $1.26 vs $1.16 🟢
💡 Consensus expected EPS of $1.16; actual $1.26 signals operational momentum not reflected in street estimates. The market is pricing low single-digit growth, while recent execution suggests mid-to-high single-digit potential.
📉 Reward/risk: 2.0:1
🏢 Business Quality: 7/10 - Diversified pharma with leading vaccines and specialty care, improving pipeline, but faces patent cliffs and competitive pressure.
📊 Valuation: cheap - P/E 10x on trailing annualized EPS ~$5 is below sector median of 13-15x.
🔮 Catalyst: Next quarterly earnings or major pipeline update (e.g., RSV vaccine readout)
💰 Entry: $50.67, stop $46.0, target $60.0
⚖️ Buy GSK at $50.67, targeting $60 (2:1 risk/reward) on undemanding P/E and pipeline-driven earnings acceleration
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/GSK0619